VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
WASHINGTON , July 22, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on July 19, 2019 , it received a notification from the U.S. Food and Drug Administration ( FDA ) stating that as part of its ongoing review of Vanda's supplemental New Drug Application
View HTML
Toggle Summary Tradipitant Effective in Preventing Motion Sickness
WASHINGTON , July 16, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean .
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
WASHINGTON , June 18, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 19, 2019 at 2:00 p.m.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at the Jefferies 2019 Global Healthcare Conference
WASHINGTON , May 31, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that Mihael H. Polymeropoulos , co-founder and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference in New York City on Tuesday, June 4, 2019 .
View HTML
Toggle Summary Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
WASHINGTON , May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week ® (DDW) 2019 in San Diego , CA.  For more information on DDW 2019, please refer to
View HTML
Toggle Summary Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results
- Total net product sales of $47.7 million in the first quarter of 2019, a 9% increase year over year - Vanda reiterates 2019 net product sales guidance of $215 million to $225 million WASHINGTON , May 1, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc.
View HTML
Toggle Summary Vanda Pharmaceuticals Appoints Phaedra Chrousos to Board of Directors
WASHINGTON , April 24, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that Phaedra Chrousos has joined Vanda's Board of Directors, effective April 23, 2019 . Following Ms. Chrousos' appointment, Vanda's Board of Directors is now comprised of six directors.
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
Conference Call and Webcast to Follow WASHINGTON , April 18, 2019 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2019 on Wednesday, May 1, 2019 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
WASHINGTON , March 7, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts on Monday, March 11, 2019 at 1:30 p.m.
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results
- Full year 2018 total revenues grew to $193.1 million, a 17% increase compared to 2017 - Full year 2019 total revenues expected to be between $215 million and $225 million WASHINGTON , Feb. 13, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and
View HTML
Toggle Summary Vanda Pharmaceuticals Takes a Stand Against Unnecessary Animal Research
Company pursuing legal action against the FDA for requiring unnecessary studies that would result in the death of dozens of dogs without legal authority. WASHINGTON , Feb. 5, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) has filed a complaint against the U.S.
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019
Conference Call and Webcast to Follow WASHINGTON , Jan. 25, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2018 on Wednesday, February 13, 2019 , after the market closes.
View HTML
Copyright © 2005-2019 Vanda Pharmaceuticals Inc. |